Cancer Nanotechnology

Symposium Co-Chairs

Mansoor M. AmijiMansoor M. Amiji
Distinguished Professor & Chair, Dept. of Pharmaceutical Sciences, Co-Director, Nanomedicine Education & Research Consortium
Northeastern University
Anil PatriAnil Patri
Deputy Director, Nanotechnology Characterization Laboratory
National Institutes of Health

Confirmed Invited Speakers

Shawn ChenNanoparticle Platforms for Drug and Gene Delivery
Shawn Chen
Senior Investigator, NIBIB/NIH
Marina DobrovolskaiaNanoparticles and the Immune System
Marina Dobrovolskaia
Senior Scientist, Nanotechnology Characterization Laboratory, NCI/NIH
Tamara MinkoTumor-Targeted Nanotherapeutics
Tamara Minko
Distinguished Professor and Chair, Rutgers, The State University of New Jersey
Mark KesterNano”solutions” for Cancer
Mark Kester
Professor, University of Virginia
Hedi  MattoussiPeptide-mediated intracellular delivery of inorganic nanocrystals: potential platforms for cancer therapy
Hedi Mattoussi
Professor, Florida State University
Shanta  DharMitochondria-targeted Delivery Systems
Shanta Dhar
Assistant Professor of Chemistry, The University of Georgia
Sangeeta  RayProstate-Specific Membrane Antigen Targeted Nanoparticles for Imaging and Therapy of Prostate Cancer
Sangeeta Ray
Assistant Professor, Johns Hopkins University
Ramesh  Bhargava Magentic Nanophosphors for Cancer Theranostics
Ramesh Bhargava
Chairman & CEO, Nanocrystals Technology

Symposium Sessions

Monday June 16

11:00Cancer Nanotechnology I
1:30Cancer Nanotechnology II
Cancer Nanotechnology - Posters 4:30

Tuesday June 17

1:30Innovation Spotlights: Bio-Pharma: GlaxoSmithKline

Wednesday June 18

10:30Gold Nanotechnoloiges II
1:30Innovation Spotlights: Med & Personal Care: BD Technologies, Unilever

Symposium Program

Monday June 16

↑ Back to Top
11:00Cancer Nanotechnology INational Harbor 3
Session chair: Mansoor M. Amiji, Northeastern University, US (bio)
11:00Nanoparticle Platforms for Drug and Gene Delivery (invited presentation)
S. Chen, NIBIB/NIH, US (bio)
11:30Prostate-Specific Membrane Antigen Targeted Nanoparticles for Imaging and Therapy of Prostate Cancer (invited presentation)
S. Ray, Johns Hopkins University, US (bio)
12:00Peptide-mediated intracellular delivery of inorganic nanocrystals: potential platforms for cancer therapy (invited presentation)
H. Mattoussi, Florida State University, US (bio)
↑ Back to Top
1:30Cancer Nanotechnology IINational Harbor 3
Session chair: Mansoor M. Amiji, Northeastern University, US (bio)
1:30Mitochondria-targeted Delivery Systems (invited presentation)
S. Dhar, The University of Georgia, US (bio)
2:00Nano”solutions” for Cancer (invited presentation)
M. Kester, University of Virginia, US (bio)
2:30Tumor-Targeted Nanotherapeutics (invited presentation)
T. Minko, Rutgers, The State University of New Jersey, US (bio)
3:00Magnetic Nanophosphors for Cancer Theranostics (invited presentation)
R. Bhargava, Nanocrystals, Inc., US (bio)
3:30Nanoparticles and the Immune System (invited presentation)
M.A. Dobrovolskaia, Nanotechnology Characterization Laboratory, Advanced Technology Program, US (bio)
↑ Back to Top
Cancer Nanotechnology - Posters 4:30Expo Hall C
-Thymoquinone nanoparticle formulation and in vitro efficacy
I.H. Fakhoury, W.S. Saad, H.U. Gali-Muhtasib, R. Schneider-Stock, American University of Beirut, LB
-Cu/TiO2-SiO2 Nanostructured Materials for Brain Cancer Treatment
T. López, E. Ortiz-Islas, P. Guevara, E. Gómez, H. Monroy, O. Novaro, National Institute of Neurology and Neurosurgery, MX
-Polyethylene Glycol (PEG) stabilized cisplatin-tethered gold nanoparticle platform for drug delivery: understanding engineered surface and drug performance by hyphenated ES-DMA with ICP-MS
J. Tan, T.J. Cho, D-H. Tsai, J. Liu, V.A. Hackley, M.R. Zachariah, University of Maryland College Park, US
-Inductive Nano Targeted Electromagnetic Therapy
M. Meymanat, Zanjan University of Medical Sciences, Zanjan, Iran, IR
-Cancer treatment with simvastatin and drug delivered chemotherapy with paclitaxel associated to a lipid nanoemulsion
I.F. Kretzer, D.A. Maria, R.A. Fock and R.C. Maranhão, University of São Paulo, BR
-The cytotoxicity BAMLET complex is regulated by the dispersion of the oleic acid and independent of α-lactalbumin component
Y. Delgado, M. Morales-Cruz, J. Hernández-Román, G. Hernández1 and K. Griebenow, University of Puerto Rico, US
-Radioimmunoliposome targeting mesothelioma cancer stem cells
J.S. Lee, T. Huang, A. Banizs, J. He, University of Virginia, US
-Oral administration of Liposomes Based on Biotin-Ceramide Conjugates in Cancer Therapy
L.-Y. Yu, S.-Y. Hung, C.-L. Lo, National Yang-Ming University, TW
-Non Toxic Water Soluble Nano Carbon Particles that can pass through the “Blood Brain Barrier”
A. Allam, S. Sarkar, M. Ghosh, B. Pakhira, Cromoz Inc, US

Tuesday June 17

↑ Back to Top
1:30Innovation Spotlights: Bio-Pharma: GlaxoSmithKlineNational Harbor 6
Session chair: Belen Martinez-Lopez, CaramelTech, MX
1:30GlaxoSmithKline - Strategic Innovation Interests
D. Bowen, GlaxoSmithKline, US
1:50Nanoparticle Analyzer (NPA)
F. Monzon, Spectradyne LLC, US
1:57Tanibirumab, a fully human anti-VEGFR2 monoclonal antibody
J.S. Yoo, PharmAbcine Inc, KR
2:04Nanocomposite Foams for Critical Size Bone Defect Repair
D. Benedict, Louisiana State University Agricultural Center, US
2:11Natural Drug Delivery Systems
K. Morris, Tranzdern Solutions, US
2:18GlaxoSmithKline Q&A

Wednesday June 18

↑ Back to Top
10:30Gold Nanotechnoloiges IINational Harbor 2
Session chair: Trevor Keel, World Gold Council, UK (bio)
10:30Developing market opportunities for gold nanorod-based technologies (invited presentation)
B. Nikoobakht, NanoRodds LLC, US (bio)
10:55TNF Bound to PEGylated Gold Nanoparticles: a Platform for a Family of Cancer Nanomedicines (invited presentation)
L. Tamarkin, G.F. Paciotti, CytImmune Sciences Inc., US (bio)
11:20Spherical Nucleic Acids (SNAs) as Potent Gene Regulation and ImmunoModulatory Agents (invited presentation)
D. Giljohann, AuraSense, US (bio)
11:45Double-targeted theranostic gold nanoparticles for treatment of brain tumors
S. Dixit, Y. Zhu, A. Moore, M. Kenney, A-M. Broome, Medical University of South Carolina, US
↑ Back to Top
1:30Innovation Spotlights: Med & Personal Care: BD Technologies, UnileverNational Harbor 6
Session chair: Steve Kubisen, George Washington University, US
1:30BD Technologies - Strategic Innovation Interests
A. Lauritano, BD Technologies, US
1:45NanoNextNL – innovating with micro and nanotechnology in the Netherlands
K. Velikov, Unilever, NL
2:00Intragastic Balloon with Novel Inflate/Deflate Mechanism and Reduced Risk in Patients
2:07iDropper: an adherence solution to improve ocular medication delivery
M. Bailey, Care Team Solutions, US
2:14AMES Technology, Inc
R. Weyel, AMES Technology, Inc., US
2:213-dimensional porous scaffolds for tissue engineering and regenerative medicine
TH Kim, Korea Institute of Industrial Technology(KITECH), KR
2:28Pharmaceutical composition and pharmacological treatment for enhancement of methadone analgesia and prevention of methadone tolerance
C. Laino, National University of La Rioja, AR
2:35A New Biomaterial, Beta-glucan Hydrogel Scaffold
JD Lee, Quegen Biotech, KR
2:42Flexible shafts
W. Krause, Flex Technology Inc., US
2:49BD Technologies, Unilever Q&A

Special Symposium

Nanotechnology has the potential to have a revolutionary impact on cancer diagnosis and therapy. It is universally accepted that early detection of cancer is essential even before anatomic anomalies are visible. A major challenge in cancer diagnosis in the 21st century is to be able to determine the exact relationship between cancer biomarkers and the clinical pathology, as well as, to be able to non-invasively detect tumors at an early stage for maximum therapeutic benefit. For breast cancer, for instance, the goal of molecular imaging is to be able to accurately diagnose when the tumor mass has approximately 100-1000 cells, as opposed to the current techniques like mammography, which require more than a million cells for accurate clinical diagnosis.

In cancer therapy, targeting and localized delivery are the key challenges. To wage an effective war against cancer, we have to have the ability to selectively attack the cancer cells, while saving the normal tissue from excessive burdens of drug toxicity. However, because many anticancer drugs are designed to simply kill cancer cells, often in a semi-specific fashion, the distribution of anticancer drugs in healthy organs or tissues is especially undesirable due to the potential for severe side effects. Consequently, systemic application of these drugs often causes severe side effects in other tissues (e.g. bone marrow suppression, cardiomyopathy, neurotoxicity), which greatly limits the maximal allowable dose of the drug. In addition, rapid elimination and widespread distribution into non-targeted organs and tissues requires the administration of a drug in large quantities, which is often not economical and sometimes complicated due to non-specific toxicity. This vicious cycle of large doses and the concurrent toxicity is a major limitation of current cancer therapy. In many instances, it has been observed that the patient succumbs to the ill effects of the drug toxicity far earlier than the tumor burden.

This symposium will address the potential ways in which nanotechnology can address these challenges. Distinguished speakers will summarize the current state of the art and future barriers. Contributions are also solicited in the following topics.

  • Science and technologies for cancer diagnostic and imaging techniques using nanoparticles as reporter platforms and contrast enhancing agents;
  • Bionalaytical nanotechnology for detection of biomarkers
  • Nanoparticle platforms polymeric nanoparticles, lipid nanoparticles, metal nanoparticles, magnetic nanoparticles, and self-assembling nanosystems;
  • Synthetic chemistry required to design and optimize new strategies for nanoparticle preparation and functionalization;
  • Therapeutic targeted and intra-cellular drug and gene delivery using nanocarriers;
  • Nanoparticles for delivery of electromagnetic energy for hyperthermia and thermal ablation of tumors;
  • Theoretical modeling of nanoparticle processes in biological and medical environments, and of drug and gene delivery;
  • Combination therapies (drug and energy delivery) using nanoparticles
  • Clinical diagnosis and therapy of prostate, breast, and liver cancer.

Topics & Application Areas

  • Cancer diagnostics
  • Cancer biomarkers
  • Cancer immunotherapeutics
  • Cancer ligands
  • Drug delivery
  • Other

Journal Submissions

Nanomedicine Journal

Nanomedicine: Nanotechnology, Biology and Medicine (Nanomedicine)

Nanomedicine NBM publishes articles on all issues related to nanomedicine, including the application of nanoscience and nanotechnology in biology and medicine.

Manuscripts must be directly or closely related to medicine (diagnosis, treatment, monitoring, prognosis and prevention of diseases) and supporting biology, especially understanding biologic mechanisms enabled by nanoscience, -engineering and -technology research, i.e.such as, research of man-made nanoscale objects, materials, and devices that improve medical procedures and outcome.

For consideration into the Nanomedicine: Nanotechnology, Biology and Medicine journal please select the “Submit to Nanomedicine: Nanotechnology, Biology and Medicine” button during the on-line submission procedure.


Sponsor & Exhibitor Opportunities

 Exhibit and Showcase
 Become a Sponsor

Please contact: Denise Lee

TechConnect Acceleration Partners:

Lockheed Martin

In Partnership with


Sponsorship Opportunities: Contact Denise Lee

Free Subscription